{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": [], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "17520770", "DateCompleted": {"Year": "2007", "Month": "05", "Day": "31"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0097-6326", "JournalIssue": {"Volume": "72", "Issue": "81", "PubDate": {"Year": "2007", "Month": "Apr", "Day": "27"}}, "Title": "Federal register", "ISOAbbreviation": "Fed Regist"}, "ArticleTitle": "Use of ozone-depleting substances; removal of essential use designations; confirmation of effective date. Direct final rule; confirmation of effective date.", "Pagination": {"StartPage": "20942", "MedlinePgn": "20942"}, "Abstract": {"AbstractText": ["The Food and Drug Administration (FDA) is confirming the effective date of April 23, 2007, for the direct final rule that appeared in the Federal Register of December 7, 2006 (71 FR 70870). The direct final rule amends the regulation to remove beclomethasone, dexamethasone, fluticasone, bitolterol, salmeterol, ergotamine tartrate, and ipratropium bromide, used in oral pressurized metered-dose inhalers, from the list of essential uses of ozone-depleting substances. None of these products is currently being marketed. This document confirms the effective date of the direct final rule."]}, "AuthorList": [{"AffiliationInfo": [], "Identifier": [], "CollectiveName": "Food and Drug Administration, HHS"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Fed Regist", "NlmUniqueID": "7808722", "ISSNLinking": "0097-6326"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Air Pollutants"}, {"RegistryNumber": "0", "NameOfSubstance": "Androstadienes"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Asthmatic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Bronchodilator Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Ethanolamines"}, {"RegistryNumber": "0", "NameOfSubstance": "Glucocorticoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Vasoconstrictor Agents"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "7S5I7G3JQL", "NameOfSubstance": "Dexamethasone"}, {"RegistryNumber": "GR88G0I6UL", "NameOfSubstance": "Ipratropium"}, {"RegistryNumber": "KGZ1SLC28Z", "NameOfSubstance": "Beclomethasone"}, {"RegistryNumber": "PR834Q503T", "NameOfSubstance": "Ergotamine"}, {"RegistryNumber": "QF8SVZ843E", "NameOfSubstance": "Albuterol"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Air Pollutants"}, {"QualifierName": ["legislation & jurisprudence"], "DescriptorName": "Air Pollution"}, {"QualifierName": ["analogs & derivatives"], "DescriptorName": "Albuterol"}, {"QualifierName": [], "DescriptorName": "Androstadienes"}, {"QualifierName": [], "DescriptorName": "Anti-Asthmatic Agents"}, {"QualifierName": [], "DescriptorName": "Beclomethasone"}, {"QualifierName": [], "DescriptorName": "Bronchodilator Agents"}, {"QualifierName": [], "DescriptorName": "Dexamethasone"}, {"QualifierName": [], "DescriptorName": "Ergotamine"}, {"QualifierName": [], "DescriptorName": "Ethanolamines"}, {"QualifierName": [], "DescriptorName": "Glucocorticoids"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Ipratropium"}, {"QualifierName": [], "DescriptorName": "Metered Dose Inhalers"}, {"QualifierName": [], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "United States"}, {"QualifierName": [], "DescriptorName": "Vasoconstrictor Agents"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2007", "Month": "5", "Day": "25", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "6", "Day": "1", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "5", "Day": "25", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17520770"]}}], "PubmedBookArticle": []}